Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Novavax NVAX incurred a fourth-quarter 2024 ... A regulatory filing is currently under the FDA’s review seeking full approval for the COVID-19 vaccine, with a final decision expected in April.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Novavax fair value estimate is US$15.08 Novavax's US$8.33... Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the ...